Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets

Biochemical Pharmacology

Volumn 60, Issue 9, 2000, Pages 1399-1407

  Schwarz, Ulrike R ^a   Kobsar, Anna L ^a,b   Koksch, Mario ^b   Walter, Ulrich ^a   Eigenthaler, Martin ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adhesion molecules; Atherosclerosis; Cyclic nucleotides; Mitogen activated protein kinases; Platelets

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; CYCLIC NUCLEOTIDE; GLYCOPROTEIN GP 39; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PADGEM PROTEIN; PROSTAGLANDIN E1; THROMBIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ALPROSTADIL; BLOOD PLATELETS; CD40 LIGAND; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; IN VITRO; MITOGEN-ACTIVATED PROTEIN KINASES; NITROPRUSSIDE; NUCLEOTIDES, CYCLIC; P-SELECTIN; P42 MAP KINASE; PHOSPHORYLATION; SUPPORT, NON-U.S. GOV'T; VASODILATOR AGENTS;

EID: 0034333365     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00452-4     Document Type: Article

References (48)

1. Gaardner A., Jonsen J., Laland S., Hellem A., Owen P.A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 192:1961;531-532.
2. Born G.V. Adenosine diphosphate as a mediator of platelet aggregation in vivo An editorial point of view . Circulation. 72:1985;741-742.
3. Hsu-Lin S., Berman C.L., Furie B.C., August D., Furie B. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem. 259:1984;9121-9126.
4. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., Kroczek R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594.
5. Fox J.E. Platelet activation New aspects . Haemostasis. 26:(Suppl 4):1996;102-131.
6. Zhang J., Falck J.R., Reddy K.K., Abrams C.S., Zhao W., Rittenhouse S.E. Phosphatidylinositol (3,4,5)-triphosphate stimulates phosphorylation of pleckstrin in human platelets. J Biol Chem. 270:1995;22807-22810.
7. Shattil S.J., Brugge J.S. Protein tyrosine phosphorylation and the adhesive functions of platelets. Curr Opin Cell Biol. 3:1991;869-879.
8. Eigenthaler M., Shattil S.J. Integrin signaling and the platelet cytoskeleton. Nelson W.J. Current Topics in Membranes. Vol. 43:1996;265-291 Academic Press, San Diego.
9. Papkoff J., Chen R.H., Blenis J., Forsman J. p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation. Mol Cell Biol. 14:1994;463-472.
10. Borsch-Haubold A.G., Kramer R.M., Watson S.P. Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. J Biol Chem. 270:1995;25885-25892.
11. Kramer R.M., Roberts E.F., Strifler B.A., Johnstone E.M. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem. 270:1995;27395-27398.
12. Kramer R.M., Roberts E.F., Um S.L., Borsch-Haubold A.G., Watson S.P., Fisher M.J., Jakubowski J.A. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem. 271:1996;27723-27729.
13. Saklatvala J., Rawlinson L., Waller R.J., Sarsfield S., Lee J.C., Morton L.F., Barnes M.J., Farndale R.W. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem. 271:1996;6586-6589.
14. McNicol A., Philpott C.L., Shibou T.S., Israels S.J. Effects of the mitogen-activated protein (MAP) kinase kinase inhibitor 2-(2′-amino-3′-methoxyphenyl)-oxanaphthalen-4-one (PD98059) on human platelet activation. Biochem Pharmacol. 55:1998;1759-1767.
15. Rossomando A.J., Payne D.M., Weber M.J., Sturgill T.W. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc Natl Acad Sci USA. 86:1989;6940-6943.
16. Eigenthaler M., Nolte C., Halbrugge M., Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem. 205:1992;471-481.
17. Eigenthaler M., Ullrich H., Geiger J., Horstrup K., Hönig-Liedl P., Wiebecke D., Walter U. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem. 268:1993;13526-13531.
18. Eigenthaler M., Walter U. Signal transduction and cyclic nucleotides in human platelets. Thromb Haemorrh Disorders. 8:1994;41-46.
19. Eigenthaler M., Lohmann S.M., Walter U., Pilz R.B. Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. Rev Physiol Biochem Pharmacol. 135:1999;173-209.
20. Massberg S., Sausbier M., Klatt P., Bauer M., Pfeifer A., Siess W., Fassler R., Ruth P., Krombach F., Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med. 189:1999;1255-1264.
21. Smolenski A., Bachmann C., Reinhard K., Hönig-Liedl P., Jarchau T., Hoschuetzky H., Walter U. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem. 273:1998;20029-20035.
22. Schwarz U.R., Geiger J., Walter U., Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Thromb Haemost. 82:1999;1145-1152.
23. Palabrica T., Lobb R., Furie B.C., Aronovitz M., Benjamin C., Hsu Y.M., Sajer S.A., Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 359:1992;848-851.
24. Neumann F.J., Marx N., Gawaz M., Brand K., Ott I., Rokitta C., Sticherling C., Meinl C., May A., Schomig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 95:1997;2387-2394.
25. Slupsky J.R., Kalbas M., Willuweit A., Henn V., Kroczek R.A., Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 80:1998;1008-1014.
26. Michelson A.D., Benoit S.E., Furman M.I., Breckwoldt W.L., Rohrer M.J., Barnard M.R., Loscalzo J. Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol. 270:1996;H1640-H1648.
27. Murohara T., Parkinson S.J., Waldman S.A., Lefer A.M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler Thromb Vasc Biol. 15:1995;2068-2075.
28. Yoshimoto H., Suehiro A., Kakishita E. Exogenous nitric oxide inhibits platelet activation in whole blood. J Cardiovasc Pharmacol. 33:1999;109-115.
29. Gries A., Bode C., Peter K., Herr A., Bohrer H., Motsch J., Martin E. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation. 97:1998;1481-1487.
30. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R.J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1:1979;1111-1114.
31. Boger R.H., Bode-Boger S.M., Thiele W., Creutzig A., Alexander K., Frolich J.C. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 32:1998;1336-1344.
32. Borsch-Haubold A.G., Kramer R.M., Watson S.P. Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Biochem J. 318:1996;207-212.
33. Borsch-Haubold A.G., Kramer R.M., Watson S.P. Phosphorylation and activation of cytosolic phospholipase A2 by 38-kDa mitogen-activated protein kinase in collagen-stimulated human platelets. Eur J Biochem. 245:1997;751-759.
34. Borsch-Haubold A.G., Pasquet S., Watson S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 273:1998;28766-28772.
35. Faure M., Bourne H.R. Differential effects on cAMP on the MAP kinase cascade Evidence for a cAMP-insensitive step that can bypass Raf-1 . Mol Biol Cell. 6:1995;1025-1035.
36. Lee A.W. Synergistic activation of mitogen-activated protein kinase by cyclic AMP and myeloid growth factors opposes cyclic AMP's growth-inhibitory effects. Blood. 93:1999;537-553.
37. Graves L.M., Bornfeldt K.E., Raines E.W., Potts B.C., Macdonald S.G., Ross R., Krebs E.G. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA. 90:1993;10300-10304.
38. Callsen D., Pfeilschifter J., Brune B. Rapid and delayed p42/p44 mitogen-activated protein kinase activation by nitric oxide The role of cyclic GMP and tyrosine phosphatase inhibition . J Immunol. 161:1998;4852-4858.
39. Komalavilas P., Shah P.K., Jo H., Lincoln T.M. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem. 274:1999;34301-34309.
40. Suhasini M., Li H., Lohmann S.M., Boss G.R., Pilz R.B. Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol Cell Biol. 18:1998;6983-6994.
41. Moule S.K., Denton R.M. The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett. 439:1998;287-290.
42. Browning D.D., McShane M.P., Marty C., Ye R.D. Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem. 275:2000;2811-2816.
43. Butt E and Walter U, Signal transduction by cyclic nucleotide-dependent protein kinases in platelets. In: Advances in Molecular and Cell Biology. Vol. 18, The Platelet (Eds. Bittar EE and Lapetina EG), pp. 311-333. JAI Press Inc., Greenwich CT, 1997.
44. Waldmann R., Walter U. Cyclic nucleotide-elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade. Eur J Pharmacol. 159:1989;317-320.
45. Ezumi Y., Nishida E., Uchiyama T., Takayama H. Thrombopoietin potentiates agonist-stimulated activation of p38 mitogen-activated protein kinase in human platelets. Biochem Biophys Res Commun. 261:1999;58-63.
46. Haller H. Modulation of endothelial function Strategy for long-term cardiovascular protection . J Hypertens Suppl. 14:1996;S27-S32.
47. Holtz J., Goetz R.M. Vascular renin-angiotensin-system, endothelial function and atherosclerosis? Basic Res Cardiol. 89:(Suppl 1):1994;71-86.
48. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.